Efficacy of novel compression gloves and stockings for prevention oxaliplatin induced peripheral neuropathy, the randomized controlled trial

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221107006

Enrollment

Registered

2022-11-07

Start date

2024-09-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer patients or gastric cancer patients with histopathological proven who plan for treatment with standard dose of Oxaliplatin-based regimen at King Chulalongkorn Memorial Hospital compression therapy oxaliplatin chemotherapy peripheral neuropathy

Interventions

a. The compression gloves and stockings were developed by a team from the biomedical engineering program, faculty of engineering, Chulalongkorn University. b. Pressure adjustable in range of 20-33 hPa

Experimental Device,No Intervention No treatment

The compression gloves and stockings,Control

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a. Colorectal cancer patients or gastric cancer patients with histopathological proven who plan for treatment with standard dose of Oxaliplatin-based regimen at King Chulalongkorn Memorial Hospital b. Age between 18 to 65 years old c. Patients with Eastern Cooperative Oncology Group (ECOG) performance status scale 0-2 d. Fully conscious patients with ability to written consent in a consent form e. Complete blood count, liver function test, and renal function test are not contraindicated for chemotherapy.

Exclusion criteria

Exclusion criteria: a. Patients who have previous neuropathy or neurological disease b. Patients who are diagnosed by history taking and physical examination as diabetes mellitus with diabetic neuropathy, active hypothyroidism, HIV infection, hepatitis viral infection, and peripheral arterial disease. c. Patients who use other complementary medicines d. Patients who are diagnosed as second primary cancer other than colorectal cancer or gastric cancer e. Patients who diagnosed as uncontrolled psychiatric disease f. Patients who are pregnant g. Patients who are in breastfeeding process

Design outcomes

Primary

Measure	Time frame
incidence of grade 2 or higher OIPN according to NCI-CTCAE 6 months NCI-CTCAE	—

Secondary

Measure	Time frame
score from the QLQ-CIPN20 questionnaire 6 months EORTC	—

Countries

Thailand

Contacts

Public ContactSurachai Leksuwankun

Faculty of Medicine, Chulalongkorn University

surachai_benz@hotmail.com0897873430

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026